BIT.AU · Biotron Limited

-

Please sign in to comment on BIT.AU

1 Comment

Admin

4 years, 1 month ago

Biotron Limited is currently in a long term downtrend where the price is trading 16.4% below its 200 day moving average.

From a valuation standpoint, the stock is 326.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1099.0.

Its net income has dropped by 15.7% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 19.3% to $-1M since the same quarter in the previous year.

Based on the above factors, Biotron Limited gets an overall score of 0/5.

Exchange	AU
ISIN	AU000000BIT4
Sector	Healthcare
Industry	Biotechnology
CurrencyCode	AUD

PE Ratio	None
Target Price	None
Market Cap	3M
Beta	-0.7
Dividend Yield	None

ABOUT

Biotron Limited

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

BIT.AU · Biotron Limited

-

Biotron Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Biotron Limited using a moving average strategy